These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11132541)

  • 1. [Value of therapy with 5-aminosalicylic acid in chemoprevention of colorectal carcinoma in ulcerative colitis].
    Herfarth H; Schölmerich J
    Z Gastroenterol; 2000 Nov; 38(11):923-5. PubMed ID: 11132541
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
    MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921656
    [No Abstract]   [Full Text] [Related]  

  • 3. Review article: maintenance therapy in patients with ulcerative colitis.
    Orchard T; Probert CS; Keshav S
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():17-22. PubMed ID: 16939425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [5-aminosalicylic acid and cancer prophylaxis?].
    Thomsen OO
    Ugeskr Laeger; 2006 May; 168(21):2047. PubMed ID: 16768920
    [No Abstract]   [Full Text] [Related]  

  • 5. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic inflammatory bowel diseases. Recurrence prevention = carcinoma prevention?].
    Vetter C
    MMW Fortschr Med; 2005 Mar; 147(13):10. PubMed ID: 15832752
    [No Abstract]   [Full Text] [Related]  

  • 8. Will a 5-ASA a day keep the cancer (and dysplasia) away?
    Rubin DT; Lashner BA
    Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence.
    Diculescu M; Ciocîrlan M; Ciocîrlan M; Piţigoi D; Becheanu G; Croitoru A; Spanache S
    Rom J Gastroenterol; 2003 Dec; 12(4):283-6. PubMed ID: 14726972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
    Ullman T; Croog V; Harpaz N; Hossain S; Kornbluth A; Bodian C; Itzkowitz S
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1225-30; quiz 1177. PubMed ID: 18848502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study.
    Velayos FS; Loftus EV; Jess T; Harmsen WS; Bida J; Zinsmeister AR; Tremaine WJ; Sandborn WJ
    Gastroenterology; 2006 Jun; 130(7):1941-9. PubMed ID: 16762617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive effects of sulphasalazine on colorectal carcinogenesis in mice with ulcerative colitis.
    Suzuki S; Sakamoto S; Mitamura T; Sassa S; Kudo H; Yamashita Y
    In Vivo; 2000; 14(3):463-6. PubMed ID: 10904883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of colorectal cancer in ulcerative colitis.
    Thomson A
    Intern Med J; 2006 Aug; 36(8):540; author reply 541. PubMed ID: 16866668
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.